Libida Reviews: What’s Actually in It, Real Cost Per Dose, and the Refund Rule

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:August 10, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 10, 2026 · Last verified: August 10, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Want to compare your options before paying?

Libida may fit a narrower reader who wants a needle-free, on-demand format, but the source review found an undisclosed dose, no public controlled trial of the exact formula, conflicting price language, and no refund. Use the free matching tool before choosing a libido-treatment path.

Find My HRT Path

Our money disclosure, up front: We earn nothing from Inner Balance or Libida. No commission, no affiliate link, no coupon code. Some alternatives linked later may include providers we earn from; those relationships are disclosed where the recommendation appears and on our affiliate disclosure page.

Most Libida reviews skip the four facts that decide this purchase: Libida is a prescription compounded tablet, not FDA-approved; Inner Balance does not publish either ingredient’s dose; no controlled trial of the exact formula is public; and Libida is excluded from refunds. Its genuine advantage is needle-free, on-demand use.

Here is the other reason we kept digging: Inner Balance currently publishes three different “cost per experience” figures for Libida on its own website — $8–$10, $20–$25, and $25 — and the number changes with the page you land on.

The seven decision facts are FDA status, public dose disclosure, exact-product evidence, current charge, real cost per tablet, refund protection, and who the product fits.

Best for you if / Not for you if

Libida may be worth discussing with the prescribing clinician if:

Your main problem is low desire itself — not pain, dryness, or difficulty with lubrication.
You want an option used around anticipated intimacy instead of a medicine taken every day.
You strongly prefer a tablet to an injection.
You understand that Libida is compounded, its public dose is undisclosed, and the evidence for the exact formula is not public.
You can absorb a non-refundable charge if it does nothing for you.

Look somewhere else first if:

You have known cardiovascular disease or high blood pressure that is not controlled.
You take oral naltrexone, or you take an oral medicine for which delayed absorption could matter.
You are pregnant, may be pregnant, or are breastfeeding and have not discussed the medication with your clinician.
You have new bleeding after menopause. That needs prompt clinical evaluation before a new libido prescription.
Sex hurts or vaginal dryness is what makes you avoid it. That is a different problem with different treatments.
The money-back guarantee is the reason you felt safe trying it.
You are postmenopausal and under 65 and want an FDA-approved oral option studied in your population.

Libida at a glance

Decision fact	Bottom line	Evidence status	Checked
What it is	Inner Balance describes Libida as a prescription compounded sublingual tablet containing bremelanotide (PT-141) and oxytocin	Provider-stated	Aug. 10, 2026
FDA status	Libida is not FDA-approved. FDA does not approve compounded drugs	Verified with FDA	Aug. 10, 2026
Dose per tablet	Not disclosed on the public Libida or pricing pages we reviewed	Not publicly verifiable	Aug. 10, 2026
Provider dosing instruction	One tablet 30–60 minutes before intimacy; no more than one tablet in 72 hours	Provider-stated	Aug. 10, 2026
Advertised price	“From $99.70/mo”	Provider-stated monthly equivalent, not the stated charge schedule	Aug. 10, 2026
Published charges	$199/10 monthly · $249 or $279/20 every two months · $299/30 every three months · $249 one-time/10	Verified on Inner Balance pages; the 20-tablet page conflicts with itself	Aug. 10, 2026
Price per tablet	$9.97 to $24.90, calculated from the published charges	The HRT Index calculation	Aug. 10, 2026
Refundable?	No. Libida is expressly named in Inner Balance’s refund exclusions	Verified policy	Aug. 10, 2026
Insurance	Inner Balance’s terms say it does not accept insurance and patients agree not to submit claims	Verified terms	Aug. 10, 2026
HSA/FSA	Inner Balance says HSA/FSA cards are accepted; eligibility remains subject to the account and administrator	Provider-stated benefit	Aug. 10, 2026
Pharmacy and testing	Inner Balance says “certified U.S. pharmacy” and “third-party tested,” but the public Libida page does not name the pharmacy, testing lab, or lot report	Partly disclosed	Aug. 10, 2026
Exact-product evidence	Inner Balance cites internal results from more than 10,000 women; no public protocol, comparator, dose, attrition table, adverse-event table, or peer-reviewed paper was located	Provider-stated, not independently validated	Aug. 10, 2026

Quick note on the name: This page is about Libida from Inner Balance, the prescription sublingual product. It is not about supplements, gummies, or other products with similar names.

Before you read further

The right online HRT provider is not the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer cannot resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care is not the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Is Libida legit, or is it a scam?

Inner Balance presents Libida as a prescription compounded product with clinician review, published terms, a patient portal, and a pharmacy-fulfillment workflow. We found no basis to call it a fake product or a scam. That does not prove the exact formula works, identify the dispensing pharmacy, or turn a compounded drug into an FDA-approved one.

Four separate questions live inside the word “legit,” and mixing them together is how people get confused.

Is the company and prescribing process real?

Inner Balance operates a live direct-pay telehealth service. Its terms of use say a provider exercises medical judgment, may decline care, does not guarantee a prescription, and may direct a prescription to a particular pharmacy based on supply, quality, consistency, clinical judgment, or state rules.

The sequence matters. Inner Balance’s public flow is assessment, payment or plan selection, provider review, prescription if approved, and shipment. Its terms say the provider can decline care and that fees may be returned if the company does not accept the member. The public pages do not explain whether the first card transaction is a settled charge or an authorization hold, or how long a return takes after a clinical denial.

That is a fair question to ask before you enter a card number:

“If the clinician does not approve Libida, when is my card charged, and how many business days does the return take?”

Is Libida FDA-approved?

No. This is the line that should never get blurry.

The FDA’s compounding guidance says compounded drugs are not FDA-approved. The agency does not verify their safety, effectiveness, or quality before they are marketed. Vyleesi is an FDA-approved, 1.75 mg bremelanotide injection with a reviewed label. Libida is a separately formulated compounded sublingual tablet that also includes oxytocin at publicly undisclosed amounts.

Those are not interchangeable products, and evidence from one cannot be pasted onto the other as though route, dose, formulation, and population do not matter.

Does the ingredient list prove the product complies with compounding law?

No. Ingredient eligibility is only one part of a much larger legal and regulatory pathway.

Bremelanotide is used in an FDA-approved injectable drug, and oxytocin is used in FDA-approved injectable drugs. That fact can be relevant to one ingredient condition under federal compounding law. It does not prove that a finished Libida prescription satisfies every applicable condition under section 503A or 503B, state pharmacy law, prescription requirements, sourcing rules, or the restrictions on products that are essentially copies of commercially available or approved drugs.

The FDA’s section 503A guidance on essentially copies also makes clear that a prescriber’s patient-specific significant-difference determination can matter in some circumstances. We cannot determine from a marketing page whether that issue applies to a particular Libida prescription, because the public page does not identify the pharmacy pathway, either ingredient’s strength, or the prescription record.

A better question than “Are these ingredients legal?” is:

“Which pharmacy fills my prescription, is it operating under 503A or 503B, and what patient-specific clinical rationale is documented for this compounded formula?”

That is not a gotcha. It is the information that lets you understand what you are actually receiving.

What the public quality claims do — and do not — establish

Inner Balance’s product page makes two reassuring claims: Libida ships from a “certified U.S. pharmacy” and is “third-party tested for purity.” Those may be meaningful positives. The same public page does not name the pharmacy, state license, accreditation, testing laboratory, test method, certificate of analysis, or lot-level report.

Public claim	What we could verify	What remains undisclosed publicly
“Clinician-reviewed”	The terms describe provider review and discretion before prescribing	Which clinician will review a particular intake before payment is completed
“Certified U.S. pharmacy”	The product page makes the claim	Pharmacy name, state licenses, accreditation, and whether the prescription is filled under 503A or 503B
“Third-party tested for purity”	The product page makes the claim	Laboratory name, analytes, potency result, contaminants panel, test date, and lot-level certificate
“HSA/FSA eligible”	The checkout marketing states it	Whether a particular plan administrator will approve the expense or request documentation
National telehealth access	Inner Balance markets broadly	A current Libida-specific state availability list

Where this leaves you: Libida does not look like a fake checkout page. The unresolved questions are not “is there a company?” They are what dose is dispensed, who compounds it, what testing can be inspected, what evidence belongs to the exact formula, and what charge you are accepting.

What’s actually in Libida, and why does the missing dose matter?

Inner Balance says Libida contains bremelanotide, also called PT-141, plus oxytocin in a sublingual tablet. It does not publish how many milligrams or units of either ingredient are in one tablet on the public pages we reviewed. Without those numbers, you cannot compare exposure, interpret the safety discussion, or assess route-specific evidence.

What bremelanotide is

Bremelanotide is a melanocortin-receptor agonist. The Vyleesi prescribing information says the precise mechanism by which it improves hypoactive sexual desire disorder is unknown. Vyleesi delivers 1.75 mg by subcutaneous injection at least 45 minutes before anticipated sexual activity.

That is the FDA-reviewed product and route. It does not establish what a sublingual tablet does at an undisclosed dose.

What oxytocin is

Oxytocin is a hormone the body makes and a drug used in FDA-approved injectable products for obstetric care. It is often discussed in connection with bonding and social behavior, but that broad biological association is not proof that added sublingual oxytocin improves female sexual desire.

This also means “hormone-free” needs precision. Libida contains no estrogen, progesterone, or testosterone according to Inner Balance’s ingredient description, but it does contain oxytocin. Calling the product free of every hormone would be inaccurate.

What HSDD means

Acquired, generalized hypoactive sexual desire disorder is more specific than “my libido is lower than I want.” The FDA labels for Vyleesi and Addyi describe low desire that causes marked distress or interpersonal difficulty, developed after a previously satisfactory level of desire, occurs across situations and partners, and is not better explained by a medical or psychiatric condition, relationship problem, or medication or drug effect.

That distinction matters. A libido drug is the wrong first answer when pain, vaginal tissue changes, a new medication, severe sleep loss, depression, trauma, relationship coercion, or another untreated health problem is driving the change.

The Label Delta: Vyleesi’s reviewed label versus Libida’s public page

This table does not claim that Vyleesi’s event rates are Libida’s event rates. It shows what is known about a defined 1.75 mg injection and what remains unknown or differently framed for the compounded tablet.

Decision point	Vyleesi — FDA-reviewed bremelanotide injection	Libida — Inner Balance’s public material
FDA status	FDA-approved prescription drug	Compounded prescription product; not FDA-approved
Population	Premenopausal women with acquired, generalized HSDD; not indicated for postmenopausal women or men	Marketed to premenopausal, perimenopausal, postmenopausal, and surgical-menopause patients
Route and dose	1.75 mg injected under the skin	Sublingual tablet; ingredient amounts not publicly disclosed
Timing	At least 45 minutes before anticipated sexual activity	Provider says 30–60 minutes before intimacy
Frequency	No more than one dose in 24 hours; more than eight doses per month is not recommended	No more than one tablet in 72 hours; no separate monthly maximum is published on the product page
Nausea	40% in trials; 13% received anti-nausea medication; 8% discontinued because of nausea	Product page calls nausea “mild,” temporary, and often limited to the first dose; no Libida-specific rate is public
Blood pressure and heart rate	Contraindicated with uncontrolled hypertension or known cardiovascular disease; transient blood-pressure rise and heart-rate reduction after each dose; not recommended for patients at high cardiovascular risk	Product page excludes uncontrolled blood pressure and “untreated heart disease,” and describes a slight temporary blood-pressure rise
Hyperpigmentation	Focal hyperpigmentation occurred in 1%; risk was higher in people with darker skin; resolution was not confirmed in every patient	Product page says about 1%, “cosmetic only,” and often fades; darker-skin risk and possible persistence are not stated there
Oral naltrexone	Label says bremelanotide may significantly reduce systemic exposure to oral naltrexone; avoid the combination	Not mentioned on the public Libida page we reviewed
Other oral medicines	Delays gastric emptying and can affect absorption of oral drugs	Not discussed on the public Libida page we reviewed
Exact-product clinical data	Two pivotal trials and a reviewed label for the injection	Internal claims are public; protocol, dose, comparator, statistical plan, attrition, and adverse-event table are not

Read that table the right way. We are not saying 40% of Libida users get nausea, or that the tablet produces the same blood-pressure curve as an injection. Nobody can calculate Libida-specific rates from Vyleesi’s label. We are saying the only FDA-reviewed safety document for bremelanotide contains issues — cardiovascular screening, naltrexone, delayed oral-drug absorption, and pigmentation persistence — that deserve a direct answer before a clinician prescribes a different bremelanotide formulation.

The number Inner Balance leaves out

A compounded route can be a legitimate response to a patient who cannot or will not use an injection. That is Libida’s strongest honest argument. The FDA-approved bremelanotide product does not come as a tablet.

But changing the route makes the dose and formulation data more important, not less. Absorption through oral mucosa is not automatically equivalent to subcutaneous injection. Inner Balance itself warns in its educational content that bioavailability can vary among compounded troches and that route changes exposure. Its public Libida page still does not disclose the amount in its own tablet.

Add these to your list:

“How many milligrams of bremelanotide and how much oxytocin are in one tablet?”
“Do you have pharmacokinetic or bioavailability data for this exact sublingual formula?”
“What monthly maximum applies in addition to the 72-hour spacing rule?”

You have now resolved the two biggest questions: what the product is and what is still missing. Jump to the 10 questions to send before you pay.

Does Libida actually work?

Bremelanotide improved desire and distress in two large trials of a known-dose injection, but it did not significantly increase satisfying sexual events. Libida’s exact bremelanotide-plus-oxytocin tablet has no public controlled trial we could locate. Inner Balance’s internal claims may be encouraging, but the missing dose, methods, comparator, and adverse-event data prevent an independent effectiveness estimate.

There are three evidence questions here. Keeping them separate is the whole game.

Layer 1: Evidence for Libida itself

Inner Balance’s product page says more than 10,000 women have tried Libida and reports improvements in desire, relaxation, openness, arousal, and satisfaction. It also says more than half felt more mentally interested in intimacy within 60 minutes and that results are often felt by the second or third attempt.

The page labels this as internal information and says the statements have not been evaluated by the FDA. We could not locate a publicly accessible protocol, comparison group, randomization method, exact dose, validated outcome definitions, baseline data, attrition numbers, statistical analysis plan, adverse-event table, or peer-reviewed publication for the exact Libida formula.

That does not prove the internal data are false. It means the public claim cannot answer the questions that turn a large user count into usable clinical evidence:

Who was included, and how was low desire diagnosed?
How many were premenopausal, perimenopausal, or postmenopausal?
What dose did each woman receive?
Was there a placebo or active comparator?
How was “improvement” defined?
How many women did not respond, stopped early, or had side effects?
Were outcomes collected once, repeatedly, or only from people who answered a follow-up survey?

Our exact finding: through August 10, 2026, we did not locate a published independent human trial of Libida’s exact dose, sublingual route, and bremelanotide-plus-oxytocin combination. If Inner Balance publishes one, this page should be updated.

Layer 2: Evidence for bremelanotide

This evidence is real and substantial — for the injection that was studied.

The RECONNECT phase 3 trials randomized 1,247 premenopausal women with acquired, generalized HSDD to bremelanotide 1.75 mg injection or placebo over 24 weeks. The FDA label reports statistically significant improvements in the two co-primary endpoints:

Sexual desire on the Female Sexual Function Index desire domain.
Distress related to low desire on the Female Sexual Distress Scale item used in the trials.

That is why Vyleesi was approved. Give the result its due.

The secondary satisfying-sexual-events endpoint did not show a statistically significant difference. In Study 1, the mean change was 0.0 with bremelanotide and −0.1 with placebo. In Study 2, it was 0.0 in both groups. The p-values were 0.76 and 0.70.

So the honest summary is not “it did nothing.” Women reported more desire and less distress. The trials did not establish a measurable increase in the number of satisfying sexual events.

Why the satisfying-events result matters here

Inner Balance’s current product page displays “satisfying events per month” as one of its internal outcome lines. Several of its educational pages also describe bremelanotide studies as showing more satisfying sexual events. The FDA-reviewed pivotal results do not support that claim as a statistically significant treatment difference.

That is the sharpest evidence gap on the page:

The outcome most likely to sound like a real-life payoff is the outcome the pivotal bremelanotide trials did not significantly improve over placebo.

This does not erase the significant desire and distress findings. It means those are the outcomes that should be described confidently, while satisfying-event claims need exact source attribution and exact-product data.

Layer 3: Evidence for oxytocin

Oxytocin is the ingredient Inner Balance says makes Libida different. The available human evidence does not establish that it adds a sexual-function benefit to this sublingual combination.

A 2015 randomized, double-blind, placebo-controlled crossover trial enrolled 30 premenopausal and postmenopausal women with sexual dysfunction. Participants used 32 IU of intranasal oxytocin or placebo before intercourse. This was not Libida, not sublingual administration, not bremelanotide plus oxytocin, and not a trial of Inner Balance’s formula.

Measure	Oxytocin	Placebo
Female Sexual Function Index	+26%	+31%
Sexual Quality of Life	+144%	+125%
Sexual Interest and Desire	+29%	+23%
Sexual Distress, where lower is better	−36%	−45%

Both periods improved, but the investigators found no significant treatment, sequence, or interaction effect that separated oxytocin from placebo.

Be fair to what that study can and cannot say. Thirty participants is small. The route was nasal. Oxytocin was tested alone. It cannot tell us whether oxytocin contributes something when combined with bremelanotide in a sublingual tablet. It also does not provide support for claiming that the added oxytocin has already been shown to improve Libida’s effectiveness.

The most accurate verdict is:

Bremelanotide has positive controlled-trial evidence for desire and distress as a 1.75 mg injection in premenopausal HSDD. The exact Libida formula does not have public controlled-trial evidence we could locate, and the most relevant randomized oxytocin trial did not separate oxytocin from placebo.

What would settle this

A useful Libida study would publish the exact formulation and dose, register the protocol before enrollment, include a credible comparator, use validated desire and distress measures, report satisfying events without changing endpoints after the fact, break results and side effects out by menopausal status, publish attrition, and disclose who designed and paid for the study.

If Inner Balance publishes that, this section becomes much easier — and much more favorable if the data earn it.

What do real Libida reviews say?

Inner Balance publishes strongly positive Libida testimonials, but they are selected for the company’s own sales page. We did not find a large, independently verifiable Libida-specific review pool that supports a success rate or star rating. The honest conclusion is not that nobody likes it; it is that public review data cannot tell you how likely your result is.

What Inner Balance’s testimonials can tell you

The product page identifies several women by first name and age and labels them verified patients. One testimonial says, “Libida honestly exceeded my expectations.” Another describes a rapid change in mood and libido. These are real statements published on a real provider page, and they belong in the review record.

They are also marketing-selected testimonials. The public page does not disclose:

How “verified patient” was determined.
How many total patients were asked for a testimonial.
How many had no effect or stopped.
Whether the women received any incentive.
The dose each woman received.
Their menopausal status, diagnosis, other medicines, or side effects.

A testimonial can show that an experience was reported. It cannot establish how typical that experience is or prove medical effectiveness.

What independent reviews can tell you

We found too little Libida-specific, independently structured review data to calculate a defensible response rate, side-effect rate, cancellation-friction rate, or average rating. Company-level reviews often mix products, shipping, customer service, Oestra, and billing. That makes them poor evidence for this tablet.

Desire is also unusually hard to attribute. A person may be changing hormone therapy, antidepressants, relationship stress, sleep, alcohol use, vaginal comfort, and expectations at the same time. A one-line “worked” or “didn’t work” review rarely tells you which variable moved.

That is why this page publishes no star rating. We have no first-party review pool and no defensible way to aggregate somebody else’s marketing testimonials, mixed product reviews, and anonymous posts into one authoritative-looking number.

How to tell a useful Libida review from a useless one

A review becomes more useful when it tells you:

Whether the reviewer is premenopausal, perimenopausal, or postmenopausal.
Whether the real problem was desire, arousal, orgasm, pain, dryness, or a medication side effect.
Whether a clinician diagnosed HSDD or the reviewer self-identified low libido.
The exact dose dispensed.
How many separate attempts were made.
What else changed at the same time, including HRT, antidepressants, alcohol, sleep, or relationship circumstances.
Whether nausea, flushing, headache, blood-pressure symptoms, or pigmentation occurred.
How long follow-up lasted.
Whether the reviewer has a financial relationship with the seller.

Most short reviews answer none of those questions. That is why they feel emotionally convincing and remain clinically weak.

How much does Libida really cost?

Inner Balance advertises Libida from $99.70 per month, but that is a rounded monthly equivalent of the $299 charge collected every three months. The published plans work out to $9.97–$24.90 per tablet if every tablet is eventually used. If an automatic subscription renews faster than you use the tablets, your effective spending per actual use can be far higher.

This is where the page earns its keep. The sticker price, per-tablet price, billing interval, and actual-use price are four different numbers.

The four published purchase structures

Purchase structure	Published charge	Tablets	Billing schedule	Price per tablet, our math
One-time purchase	$249	10	Charged once	$24.90
Monthly subscription	$199	10	Every month	$19.90
Two-month subscription	$249, but the same page also says $279 will be charged	20	Every two months	$12.45 or $13.95
Three-month subscription	$299	30	Every three months	$9.97

Source: Inner Balance’s female libido treatment pricing guide and low sex drive medication page, read August 10, 2026. Per-tablet figures calculated by The HRT Index.

Three things jump out.

1. The $99.70 headline is a monthly equivalent, not the stated monthly charge

The arithmetic is straightforward:

$299 ÷ 3 = $99.67, which rounds to $99.70.

The product page’s headline is therefore reconcilable, but incomplete by itself. The published plan says $299 is collected every three months. A reader seeing “from $99.70/mo” could reasonably assume a $99.70 monthly charge, and that is not the stated billing schedule.

The clean disclosure would be: $299 charged every three months, equivalent to $99.67 per month.

2. One plan line contains two different charges

Inner Balance’s low-sex-drive page currently says the 20-tablet option is $249 and then, in the same line, says $279 is charged every two months.

That changes the per-tablet cost from $12.45 to $13.95. Neither figure should be treated as the checkout price until the cart confirms it.

Ask:

“For the 20-tablet plan, what amount will be charged today and at the next renewal: $249 or $279?”

3. Inner Balance publishes three different per-experience figures

Inner Balance page	Published Libida cost per experience
Female libido treatment pricing guide	$8–$10
Low sex drive medication guide	$20–$25
Natural ways to increase female libido	About $25

The math explains part of the spread. About $25 matches the one-time 10-tablet purchase. About $10 matches the 30-tablet plan only if all 30 tablets are eventually used. The $20–$25 range resembles the monthly or one-time options. The problem is that the pages often present these as a general product cost rather than attaching each number cleanly to a named plan and billing schedule.

The subscription-use mismatch nobody shows you

The pivotal Vyleesi trials do not tell us how often Libida users take Libida. They do show that most injection-trial participants used bremelanotide two or three times per month and no more than once a week. The median was 10 injections across the 24-week controlled period.

Use that only as a planning scenario, not a claim about Libida behavior.

If your subscription keeps renewing while you use two or three tablets a month, this is what happens:

Plan	Charge before next refill	Uses at 2/month	Effective spend per use before refill	Tablets left when refill arrives	Uses at 3/month	Effective spend per use before refill	Tablets left when refill arrives
$199 monthly / 10 tablets	$199	2	$99.50	8	3	$66.33	7
$249 every 2 months / 20 tablets	$249	4	$62.25	16	6	$41.50	14
$279 every 2 months / 20 tablets	$279	4	$69.75	16	6	$46.50	14
$299 every 3 months / 30 tablets	$299	6	$49.83	24	9	$33.22	21

That table measures cash spent divided by actual uses before the next automatic charge. It does not mean each tablet permanently costs $33–$100. If you cancel after the first shipment and eventually use every tablet, the per-tablet price returns to $9.97–$24.90. The problem is accumulation: an automatic refill can arrive with most of the previous supply still sitting there.

Libida true-cost worksheet

Before choosing a plan, calculate three numbers:

1. Expected uses before renewal = realistic uses per month × months in the billing cycle.
2. Effective subscription spend per actual use = charge ÷ expected uses before renewal.
3. Unused tablets at renewal = tablets shipped − expected uses before renewal.

Example for the three-month plan at three uses per month:

Expected uses before renewal: 3 × 3 = 9.
Effective spend per actual use before renewal: $299 ÷ 9 = $33.22.
Unused tablets when the next 30 arrive: 30 − 9 = 21.

That is the number to compare with your budget and your willingness to cancel quickly — not just $9.97 per tablet.

The Vyleesi price comparison changed

A cash benchmark of roughly $250–$300 per Vyleesi injection is no longer a responsible current comparison without context.

As of August 10, 2026, the official Vyleesi site says most eligible commercially insured patients may pay as little as $0 for a four-dose box, and qualifying patients without insurance coverage can obtain a four-dose box for $99 through the stated program. That second figure is $24.75 per dose. Eligibility, government-insurance exclusions, state law, and program availability apply, and the program can change.

That does not make Vyleesi the universal winner. It is an injection and is indicated for premenopausal women with acquired, generalized HSDD. It does mean Inner Balance’s pages that frame Vyleesi as automatically costing hundreds per injection are not a complete current comparison.

What about HSA and FSA funds?

Inner Balance says HSA/FSA cards are accepted. Its refund policy also says HSA/FSA purchases may be eligible for a refund generally — but the same policy separately names Libida in the no-refund list. The product-specific exclusion is the material fact here.

Do not count a tax-bracket example as guaranteed savings. Account eligibility and documentation rules depend on the plan and administrator. Ask for a receipt or letter of medical necessity if your administrator requires one.

The lowest-risk way to test the economics

The one-time 10-tablet purchase avoids an automatic refill, but its first charge is $249 and it costs $24.90 per tablet. The monthly subscription has the lowest first charge at $199, but it also creates the fastest renewal. The three-month plan costs $299 and has the lowest calculated price per tablet, but it creates the largest inventory if your use is occasional.

The decision is not simply “cheapest tablet.” It is:

Lowest first charge: $199 monthly subscription — with another charge due in one month unless cancellation is processed.
No automatic renewal: $249 one-time purchase.
Lowest eventual price per tablet: $299 three-month subscription, if you use the supply and control the renewal.
Worst fit: any automatic refill cycle that outruns how often you realistically use it.

You now know what it costs better than a headline can tell you. Save the true-cost worksheet, choose your realistic use frequency, and screenshot the charge shown at checkout before submitting payment.

Can you get a refund on Libida?

No. Inner Balance’s current refund policy names Libida in the list of purchases that do not qualify. “Cancel anytime” can stop future subscription charges when processed in time; it does not reverse a completed Libida purchase, and refunds are not automatic when any Inner Balance subscription is cancelled.

The refund policy limits its guarantees to qualifying Oestra subscription fees and qualifying BodyMatched purchases. Libida is expressly excluded.

That means all four of these statements can be true at once:

Inner Balance lets you cancel a subscription.
A care team handles refund requests through secure chat.
HSA/FSA purchases can be refundable when the underlying product qualifies.
Libida itself does not qualify for a refund.

Cancel anytime does not mean refund anytime

Cancelling addresses future renewals. A refund addresses money already charged. The product page emphasizes cancellation flexibility, but the no-refund rule lives in the separate policy.

This is the damaging admission that matters most because the product has an undisclosed dose and no public controlled trial of the exact formula. You are accepting both clinical uncertainty and financial finality.

The no-refund rule buys you nothing

The missing guarantee is not what makes Libida on-demand. A product can be used on demand whether its seller offers a guarantee or not.

The genuine upside is separate: Libida is marketed as a needle-free tablet used around anticipated intimacy, with no daily estrogen, progesterone, or testosterone regimen. For someone who refuses injections and does not want a daily pill, that convenience may still outweigh the no-refund rule.

But do not pretend the rule is a feature. If protection against wasting $249 or $299 is your priority, choose another route.

How to cancel a Libida subscription

Inner Balance’s terms route termination through the member account, and its refund policy directs requests to secure chat. Use a simple paper trail:

1. Log in to your account and open secure chat.
2. State that you want the Libida subscription cancelled and no future renewal charged.
3. Ask for the effective date in writing.
4. Ask whether the next order has already been sent to the pharmacy.
5. Save screenshots of the request and response.
6. Confirm that your dashboard reflects cancellation.
7. Check the payment method on the next scheduled billing date.

Do it before the renewal date. The terms say monthly, two-month, and three-month fees are collected in advance.

If non-refundable uncertainty is a dealbreaker: compare FDA-approved and off-label clinical routes for low desire before you pay.

Does Libida work after menopause?

Inner Balance markets Libida to postmenopausal women, but we found no public controlled trial of the exact formula broken out by menopausal status. Vyleesi’s FDA label does not indicate bremelanotide for postmenopausal women. Women under 65 now have an FDA-approved oral option, and transdermal testosterone has stronger off-label evidence for postmenopausal HSDD.

If you are postmenopausal, this section may save you more money than any coupon.

First, separate low desire from painful sex

Low desire and painful sex are not the same problem.

Dryness, burning, irritation, urinary symptoms, and pain with penetration can be part of genitourinary syndrome of menopause. The tissue problem can make avoidance look like a desire problem: you stop wanting an experience your body has learned will hurt.

Low-dose vaginal estrogen and other GSM treatments are designed for those tissue symptoms. A brain-acting desire drug does not rebuild painful vaginal tissue. If pain or dryness is present, address it directly before deciding that desire itself is the only target.

A useful self-check is simple:

“I want intimacy, but it hurts or feels dry.” Start with the pain/GSM path.
“Sex is comfortable, but interest is absent and the change bothers me.” Discuss the HSDD path.
“It is both.” Treating pain first can clarify what desire problem remains.

See our menopause and libido guide for the symptom-level decision path.

What changed for postmenopausal women in December 2025?

On December 13, 2025, the FDA approved an expanded indication for Addyi (flibanserin) to women under 65 with acquired, generalized HSDD, regardless of menopause status. Its current label includes a phase 3 study in 902 postmenopausal women under 65: 447 received Addyi and 455 received placebo.

That matters because older comparisons saying no FDA-approved desire medication exists after menopause are now stale.

Addyi is not an on-demand substitute for Libida. It is a 100 mg tablet taken every night at bedtime. The label says to stop after eight weeks if symptoms do not improve. It carries a boxed warning about severe low blood pressure and fainting in certain situations, including alcohol taken too close to the dose and use with moderate or strong CYP3A4 inhibitors.

The current alcohol instructions are more specific than “never drink”: after one or two standard drinks, wait at least two hours before the bedtime dose; after three or more drinks, skip that night’s dose; and do not drink until the next day after taking it.

What does the evidence say about testosterone after menopause?

The Global Consensus Position Statement and the ISSWSH clinical guideline identify HSDD in postmenopausal women as the only evidence-based indication for testosterone therapy in women. Trials using physiological female-range dosing show an average increase of about one satisfying sexual event per month above placebo, along with improvements in desire, arousal, orgasm, pleasure, responsiveness, and sexual distress.

Three limits have to travel with that evidence:

1. No testosterone product is FDA-approved for women in the United States. Treatment is off-label and commonly uses a carefully reduced amount of a product approved for men.
2. Testosterone is a Schedule III controlled substance. It requires a prescription, clinician oversight, and monitoring; this is not an over-the-counter libido supplement.
3. The consensus evidence does not support compounded testosterone, pellets, injectables, or dosing that raises levels above the normal premenopausal female range. The evidence is centered on appropriately dosed transdermal therapy.

Where does that leave Libida after menopause?

The case against Libida: no public controlled trial of its exact formula, an undisclosed dose, no FDA approval, no refund, and no Vyleesi indication for postmenopausal women. Addyi is now FDA-approved for women under 65, and physiological transdermal testosterone has consensus-backed off-label evidence.

The case for Libida: it is marketed as needle-free and on-demand. Addyi is nightly. Testosterone is ongoing. Neither gives a postmenopausal woman a studied, FDA-approved tablet she takes only on the nights she chooses.

That is the real trade-off: on-demand convenience versus product-specific evidence, dose transparency, and approval status.

If you are postmenopausal, do not let one checkout page define the menu. Compare menopause-focused online care models that can assess pain, GSM, medications, Addyi eligibility, and off-label testosterone before you commit to one formula. Affiliate relationships are disclosed on that page.

How do Libida, Vyleesi, Addyi, and testosterone compare?

Libida is the only compounded combination in this comparison. Vyleesi is the only FDA-approved on-demand bremelanotide product. Addyi is the FDA-approved daily pill for eligible women under 65 before or after menopause. Transdermal testosterone has the strongest consensus-supported evidence for postmenopausal HSDD but no FDA-approved female product in the United States.

Decision factor	Libida	Vyleesi	Addyi	Physiological transdermal testosterone
What it is	Compounded bremelanotide + oxytocin	Bremelanotide	Flibanserin	Testosterone applied through skin
FDA status	Not FDA-approved	FDA-approved	FDA-approved	No FDA-approved female product in the U.S.; off-label use
Population supported by approval/evidence	No FDA-approved population; Inner Balance markets across menopause stages	Premenopausal women with acquired, generalized HSDD	Women under 65 with acquired, generalized HSDD, regardless of menopause status	Consensus-supported for appropriately assessed postmenopausal women with HSDD
Route and public dose	Sublingual tablet; amounts not publicly disclosed	1.75 mg subcutaneous injection	100 mg oral tablet	Product and amount vary; clinician adjusts to physiological female range
On-demand?	Provider markets it that way	Yes	No — nightly	No — ongoing
Public exact-product evidence	No controlled trial of the exact formula located	Two pivotal phase 3 trials and FDA label	FDA-reviewed trials and label	Multiple randomized trials synthesized in consensus guidance
Current published cost	$9.97–$24.90 per tablet from current Inner Balance charges	Official program says as little as $0 per four-dose box for eligible commercially insured patients; $99 per four-dose box for qualifying uncovered patients	Official program advertises as little as $20/month for eligible insured patients and $149/month cash through its stated pharmacy route	Varies by prescribed product, pharmacy, insurance, and amount; confirm before filling
Main advantage	Needle-free, on-demand format	Known dose, FDA-approved, on-demand	FDA-approved oral route before and after menopause under 65	Strongest evidence base for postmenopausal HSDD
Main limitation	Undisclosed dose, compounded, no exact-formula trial, no refund	Injection, nausea common, not indicated after menopause	Daily dosing, interaction/alcohol precautions, dizziness and sleepiness	Controlled substance; off-label; monitoring required; no approved female product

Prices and assistance programs can change. The figures above were checked August 10, 2026; confirm eligibility and the exact charge before relying on them.

Which route fits which situation?

Premenopausal, wants on-demand, accepts an injection: Vyleesi offers the known dose and FDA-reviewed route.
Premenopausal, refuses injections, accepts compounded uncertainty: Libida may be a discussion worth having after dose, pharmacy, interactions, and refund terms are clear.
Under 65 and wants an FDA-approved pill: Addyi is the oral route, but it is nightly rather than on-demand.
Postmenopausal with distressing low desire: compare Addyi and physiological transdermal testosterone before treating Libida as the default.
Pain or dryness is the main barrier: use the GSM path, not a desire drug as the first move.
Oral naltrexone or significant cardiovascular history: Libida and Vyleesi require especially careful screening because of bremelanotide’s labeled risks and interaction.

What are Libida’s side effects, and who should not take it?

Inner Balance lists nausea, flushing, headache, temporary blood-pressure elevation, and uncommon skin darkening. No public Libida-specific adverse-event rates were located. Vyleesi’s label provides the best characterized bremelanotide safety data, but its 1.75 mg injection rates cannot be assigned to an undisclosed-dose sublingual tablet.

Nausea is the clearest known bremelanotide signal

In Vyleesi’s trials, nausea occurred in 40% of patients. Thirteen percent received anti-nausea medication, and 8% discontinued because of nausea. Nausea occurred most often after the first dose and became less common with later doses.

Inner Balance describes Libida nausea as mild and often limited to the first dose. Without an adverse-event table for the exact formula, that softer description cannot be converted into a Libida rate.

Blood pressure and heart history are not checkbox details

Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. Its label says blood pressure rises and heart rate falls after each dose, generally peaking within hours and resolving within 12 hours. It is not recommended for patients at high cardiovascular risk.

Inner Balance’s page excludes uncontrolled blood pressure and untreated heart disease, but “untreated” is not the Vyleesi label’s boundary. A treated cardiovascular diagnosis is still a cardiovascular diagnosis. Bring actual readings, diagnoses, and medications to the prescriber rather than relying on a broad quiz answer.

Oral naltrexone is a specific interaction

Bremelanotide can substantially reduce exposure to oral naltrexone by slowing gastric emptying. Vyleesi’s label says to avoid the combination. Oral naltrexone is used for alcohol use disorder, opioid use disorder, and other off-label purposes.

The same delayed-gastric-emptying effect can matter for other oral drugs whose timing or absorption is clinically important. Ask about your entire medication list, not just hormones.

Skin darkening may not always reverse

Vyleesi’s trials reported focal hyperpigmentation in about 1% of patients, including the face, gums, and breasts. The label says risk was higher in patients with darker skin and that resolution was not confirmed in every patient after discontinuation.

Inner Balance’s page calls the effect cosmetic and says it often fades. “Often” is not “always.” That distinction belongs in the decision.

Who should stop and get a direct clinical answer first?

Do not treat this list as a diagnosis or a complete contraindication screen. Pause the checkout and speak directly with a clinician if:

You have uncontrolled high blood pressure, known cardiovascular disease, or high cardiovascular risk.
You take oral naltrexone or a time-sensitive oral medicine.
You are pregnant, may be pregnant, or are breastfeeding.
You have new bleeding after menopause.
Your low desire began after starting or changing another medication.
Pain, dryness, trauma, depression, severe anxiety, coercion, or relationship distress is the larger problem.
You cannot identify what dose or pharmacy you would receive.

Seek urgent medical care for chest pain, fainting, severe or persistent vomiting, a severe sudden headache, trouble breathing, facial or throat swelling, or another possible emergency after a dose.

Where do Inner Balance’s current Libida pages disagree or leave gaps?

The biggest problems are not hidden in fine pharmacology. They are purchase facts: two charges for one 20-tablet plan, three “cost per experience” figures, a monthly-equivalent headline that is not the billing schedule, and outcome language that outruns the pivotal bremelanotide endpoint. Each conflict below was present on live Inner Balance pages reviewed August 10, 2026.

Issue	One public claim	The conflicting fact or missing disclosure	What to do before paying
20-tablet charge	“$249 for 20 tablets”	The same plan text also says “$279 charged every 2 months”	Screenshot checkout and ask which amount will be charged now and at renewal
Cost per experience	$8–$10 on several pages	$20–$25 on another page and about $25 on another	Calculate from the exact plan, not the marketing phrase
“From $99.70/mo”	Headline monthly equivalent	The published three-month charge is $299, paid in advance	Budget for the charge schedule, not the normalized headline
Satisfying sexual events	Inner Balance says bremelanotide studies show more satisfying sexual events	The pivotal trials did not show a significant treatment-group difference on that outcome	Treat desire/distress evidence separately from event-frequency claims
Postmenopausal use	Inner Balance says Libida works after menopause	Vyleesi is not indicated after menopause, and no public exact-Libida trial by menopause status was located	Compare Addyi and testosterone evidence before deciding
Dose transparency	Product instructions say one tablet	Neither ingredient’s amount is public on the pages reviewed	Get both amounts in writing before filling
Pharmacy and testing	“Certified U.S. pharmacy” and “third-party tested”	No pharmacy name, testing lab, method, or lot result is shown publicly	Ask for the pharmacy and available lot-level documentation
Vyleesi cost comparison	Inner Balance pages use figures ranging from about $50–$70 to $250+ per injection	The current official Vyleesi program advertises qualifying boxes at $0 or $99 for four doses	Compare current eligible net cost, not a single old cash benchmark
Hormone framing	Libida is positioned as avoiding a hormone regimen	Oxytocin is itself a hormone; the accurate distinction is no estrogen, progesterone, or testosterone in the disclosed formula	Use precise language when comparing it with HRT
Refund confidence	“Cancel anytime” appears prominently	Libida is expressly excluded from the refund policy	Separate cancellation from refund protection

None of these proves the product cannot work. They prove the answer you need is the version that applies to your prescription and your card, not whichever sentence appeared on the landing page.

Screenshot the dose instructions, price, renewal date, refund rule, and any written answers before paying. That is not paranoia. It is basic documentation when the seller’s own pages do not line up.

What should you confirm before you pay for Libida?

Ten questions close the gaps that materially change this decision: dose, pharmacy, testing, route evidence, cardiovascular screening, drug interactions, monthly maximum, exact charge, refund status, and state availability. Get the answers in writing. A polished product page cannot substitute for the prescription and billing terms that apply to you.

1. What is the exact dose? “How many milligrams of bremelanotide and how many units or milligrams of oxytocin are in one tablet?”
2. Which pharmacy fills it? “What is the dispensing pharmacy’s name and state license, and is this filled under a 503A or 503B pathway?”
3. What does third-party testing mean here? “Which laboratory tests Libida, what is tested, and can I see a certificate or lot result for the product I receive?”
4. What data exist for the exact route and formula? “Do you have pharmacokinetic or controlled clinical data for this sublingual bremelanotide-plus-oxytocin formulation?”
5. How does my cardiovascular history change the decision? “Given my diagnoses, readings, and medications, what blood-pressure or heart screening do you require?”
6. Do my oral medications interact? “I take [list every drug and supplement]. Does delayed gastric emptying or any other interaction matter?”
7. Is there a monthly maximum? “In addition to one tablet every 72 hours, is there a maximum number of tablets per month?”
8. What will my card be charged? “Which plan creates the $99.70 monthly equivalent, what is charged today, and what amount and date apply to renewal?”
9. Is any part refundable? “Please confirm in writing that Libida is non-refundable and explain what happens if the clinician declines the prescription.”
10. Is it available in my state? “Can the clinician prescribe and the named pharmacy dispense Libida to my current state?”

Then verify the clinician and pharmacy through the relevant state licensing boards. Do not rely on a badge alone when the actual license records are available.

How did The HRT Index verify this Libida review?

We compared Inner Balance’s live product, pricing, terms, refund, and educational pages with FDA labels, federal compounding materials, the pivotal bremelanotide trials, the controlled oxytocin trial, current Addyi labeling, testosterone consensus guidance, and federal controlled-substance schedules. Commercial facts were checked August 10, 2026 and labeled as verified, provider-stated, calculated, or not publicly verifiable.

The HRT Index Verification Standard is our documented process: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. It is a process, not a numeric score.

We evaluate the decision through five pillars, always in this order:

Clinical legitimacy: Inner Balance describes a clinician-review and prescription workflow. The exact dispensing pharmacy and Libida-specific state access are not public.
Care quality: The company offers portal access and care-team messaging. We did not purchase Libida, test response time, or experience follow-up firsthand.
Medication fit: Ingredients, route, and provider instructions are public; exact amounts, route-specific pharmacokinetics, and controlled exact-formula evidence are not.
Price transparency: Current plan charges can be assembled, but the 20-tablet line conflicts and the cost-per-experience claims vary.
Access: The program is direct-pay and says HSA/FSA cards are accepted. Insurance claims are not accepted, and a current Libida-specific state list was not located.

What we verified

Inner Balance’s ingredient and sublingual-route description.
Current plan charges and the $99.70 monthly-equivalent reconciliation.
The three different current “cost per experience” claims.
The explicit Libida refund exclusion and general cancellation route.
Direct-pay/no-insurance terms and provider-stated HSA/FSA acceptance.
Vyleesi’s FDA status, indication, dose, frequency, warnings, interaction, and trial outcomes.
The controlled oxytocin trial’s treatment and placebo results.
Addyi’s current under-65 indication, postmenopausal trial size, dosing, warning, and stop rule.
The consensus position on physiological transdermal testosterone for postmenopausal HSDD.
Testosterone’s Schedule III status under current federal rules.

What remains unverified publicly

Milligrams or units of each Libida ingredient per tablet.
Pharmacokinetic data for the exact sublingual formula.
A controlled independent trial of Libida’s exact combination and dose.
Protocol, comparator, attrition, adverse-event table, and peer-reviewed report for the provider’s “10,000+ women” internal data.
Dispensing pharmacy identity and compounding pathway for a particular order.
Testing laboratory, methods, acceptance limits, and lot-level report.
Complete Libida availability by state.
Which of the two published 20-tablet charges appears at a particular checkout.
Actual cancellation response time or care experience, because we did not purchase the product.

What needs to be rechecked after publication?

Element	Refresh cadence	Verification method
Price, plan size, charge schedule, promotions	Monthly	Product page, pricing pages, and a dated checkout capture
Refund and cancellation policy	Monthly	Terms and refund-policy pages; archive dated screenshots
Pharmacy, testing, and state availability	Quarterly or when the product page changes	Public disclosures, care-team confirmation, and state license records
Vyleesi and Addyi labels and assistance programs	Monthly for money pages; immediately after an FDA update	DailyMed/FDA label and official program terms
FDA compounding policy or enforcement	Quarterly and after relevant agency action	FDA compounding pages, guidances, warning letters, and enforcement notices
Testosterone guidance and federal schedule	Quarterly	Consensus/guideline updates and current eCFR
Internal links, privacy language, and quiz claims	Quarterly	Live The HRT Index pages

See our full methodology for how provider facts are collected and dated.

Frequently asked questions about Libida

Is Libida FDA-approved?

No. Libida is a compounded prescription product, and compounded drugs are not FDA-approved. Vyleesi is an FDA-approved 1.75 mg bremelanotide injection, but that does not confer approval on Libida’s different sublingual combination.

Is Libida the same as Vyleesi?

No. Libida is a compounded sublingual tablet containing bremelanotide plus oxytocin at publicly undisclosed amounts. Vyleesi is an FDA-approved injection containing 1.75 mg bremelanotide. Route, formulation, dose, indication, and evidence differ.

Does Libida work?

Some provider-published testimonials report a clear effect, and Inner Balance cites internal data from more than 10,000 women. We found no public controlled trial of the exact Libida dose, route, and combination. Bremelanotide injection trials showed significant improvements in desire and distress, but not a significant increase in satisfying sexual events.

What is the Libida dose?

Inner Balance tells patients to take one tablet 30–60 minutes before intimacy and no more than once every 72 hours. The public pages we reviewed do not disclose how much bremelanotide or oxytocin is in the tablet. Ask for both amounts before the prescription is filled.

How fast does Libida work, and how long does it last?

Inner Balance says effects can begin in 30–60 minutes and last 24–72 hours. Those are provider-stated figures. We did not locate independent pharmacokinetic or controlled outcome data for the exact sublingual formula.

How much does Libida cost?

Current published charges range from $199 for 10 subscription tablets to $299 for 30 tablets every three months, plus a $249 one-time 10-tablet purchase. One page gives both $249 and $279 for the 20-tablet plan. Calculated price is $9.97–$24.90 per tablet, but automatic-refill economics depend on how often you actually use it.

Can you get a refund on Libida?

No under the current policy. Inner Balance expressly names Libida in its refund exclusions. Cancelling can stop future renewals if processed in time; it does not create a refund for the completed Libida purchase.

How do you cancel Libida?

Use the member account and secure chat, state that you are cancelling all future Libida renewals, request the effective date in writing, and save the response. Do it before the renewal date because subscription fees are charged in advance.

Does insurance cover Libida?

Inner Balance’s terms say it does not accept insurance and members agree not to submit claims. The company says HSA/FSA cards are accepted, but account eligibility and documentation are determined by the plan administrator.

Can you take Libida with HRT?

Inner Balance markets Libida for use alongside hormone therapy, but that does not answer whether the combination fits your history or medication list. Give the prescriber every prescription, over-the-counter drug, and supplement you use, and separate desire from pain or GSM symptoms.

Does Libida work after menopause?

Inner Balance says it does, but no public controlled exact-product study by menopausal status was located. Vyleesi is not indicated for postmenopausal women. Women under 65 can now discuss FDA-approved Addyi, and physiological transdermal testosterone has stronger consensus-supported evidence for postmenopausal HSDD.

Does Libida darken skin?

Inner Balance lists uncommon skin darkening. Vyleesi’s label reports focal hyperpigmentation in about 1% of trial patients, with higher risk in darker skin and no confirmed resolution in every patient. That injection rate cannot be assigned directly to Libida, but the risk deserves discussion.

Is Libida a controlled substance?

Bremelanotide and oxytocin were not listed in the current federal controlled-substance schedules reviewed August 10, 2026. Testosterone, discussed as an alternative, is a Schedule III controlled substance and requires a prescription and clinical oversight.

Is Libida available in every state?

A current public Libida-specific state list was not located. Confirm that a clinician can prescribe and the named pharmacy can dispense to your state before relying on national marketing language.

Why does this page not give Libida a star rating?

Because The HRT Index has not used Libida and no large independent, product-specific review pool was available to aggregate defensibly. A numeric rating would look more certain than the evidence allows. The page gives you the evidence ledger instead.

The bottom line on Libida reviews

Libida appears to be a real prescription compounded product sold through a functioning telehealth workflow. It is not FDA-approved, and calling it equivalent to Vyleesi would be wrong.

Its honest appeal is easy to understand: a needle-free tablet used around anticipated intimacy, rather than an injection or a medicine taken every day.

Its honest liabilities are just as clear: neither ingredient’s dose is public, controlled evidence for the exact combination is not public, the seller’s price language conflicts across pages, the pharmacy and testing details are incomplete, and the purchase is non-refundable.

If you are premenopausal, strongly needle-averse, want an on-demand format, and can accept the uncertainty and financial risk, Libida may be a defensible prescription to discuss after the clinician answers the ten questions above.

If you are postmenopausal, compare Addyi and physiological transdermal testosterone before making Libida the default. Neither is an on-demand equivalent, but both have evidence that more directly fits your life stage.

If sex hurts or feels dry, start with the GSM path. Spending $249–$299 on a desire product before treating painful tissue is the expensive way to solve the wrong problem.

If the money-back guarantee was your safety net, it is not available for Libida. Choose another route.

You do not need permission to want your desire back. You do deserve to know what you are buying.

Still not sure which HRT program is right for you? Take our free matching quiz — about 90 seconds.

The HRT Index's Find My HRT Path tool is free, requires no email, and does not diagnose or prescribe. It helps separate desire from pain, flags when online care is not the right starting point, and maps your situation to an appropriate next step. Health-data handling is explained in our consumer health data privacy notice and privacy policy.

Sources

Last verified: August 10, 2026. Editorial research by The HRT Index — educational only, not medical advice, and not medically reviewed by a clinician as of this date.

Not sure whether Libida is the right starting point?

Read the menopause and libido guide, compare bremelanotide prescription routes, review the best telehealth HRT providers, or use the free Find My HRT Path tool.

Keep reading: